Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 3/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 8/20 | 0.50 |
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23355177 | 0.89 | CAPN1 (0.58) | ITGA4CAPN1CTSLPSMB1PSMB5 | |
| SCHEMBL24008869 | 0.84 | CAPN1 (0.48) | ITGA4ITGB1CAPN1CTSSCTSK | |
| SCHEMBL29961431 | 0.79 | ITGA4 (0.62) | ITGA4ITGB1CAPN1CTSLPSMB1 | |
| SCHEMBL24008794 | 0.79 | ITGA4 (0.62) | ITGA4ITGB1CAPN1CTSLPSMB1 | |
| SCHEMBL23355169 | 0.78 | CAPN1 (0.58) | ITGA4ITGB1CAPN1PSMB5 | |
| SCHEMBL24862869 | 0.78 | CAPN1 (0.69) | CAPN1CTSL | |
| SCHEMBL28549630 | 0.78 | ITGA4 (0.53) | ITGA4ITGB1CTSLEPHX2PSMB1 | |
| SCHEMBL5468240 | 0.77 | ITGA4 (0.54) | ITGA4ITGB1EPHX2PSMB1PSMB5 | |
| SCHEMBL23355180 | 0.75 | CAPN1 (0.49) | ITGA4ITGB1CAPN1 | |
| SCHEMBL23571311 | 0.74 | CTSB (0.56) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| EP-3820864-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | Blade Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112703188-A | Method for treating liver fibrosis using calpain inhibitor | 布莱德治疗公司 | 2021-04-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPN1, CAPNS1, CAPN2 | ITGA4 3780/4885ITGB1 2184/4885CAPN1 1/4885 |
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | ITGA4 2428/4885ITGB1 2042/4885CAPN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.